Medical/Pharmaceuticals
Pulse Medical receives FDA Breakthrough Device Designation for its μFR® system
SHANGHAI, May 26, 2023 /PRNewswire/ -- Pulse Medical Technology, Inc. (Pulse Medical) 4th generation μFR® system has received an FDA Breakthrough Device designation. Pulse Medical, founded in 2015, located in Shanghai, China, is dedicated to developing innovative technology for precise diagnosi...
2023-05-26 22:08
4637
ProfoundBio Announces Further Advancement of Lead Programs - PRO1184 (Rinatabart Sesutecan) and PRO1160 in the Clinic
* PRO1160 first patient dosed in the US * China NMPA clearance for PRO1184 (rinatabart sesutecan, Rina-S) and PRO1160 to initiate clinical trials * Rina-S preliminary clinical data is encouraging SUZHOU, China and WOODINVILLE, Wash., May 26, 2023 /PRNewswire/ -- ProfoundBio, a clinical-stage...
2023-05-26 20:00
3487
FivepHusion Announces Strategic Collaboration with Treehill Partners and Syneos Health
Supporting FivepHusion's Global Development and Commercialization Strategy SYDNEY, May 26, 2023 /PRNewswire/ -- FivepHusion, an advanced clinical-stage biotechnology company, today announced its collaboration with Treehill Partners, aNew York-based strategic and financial advisory firm specializi...
2023-05-26 13:42
3111
Ascentage Pharma Presents Updated Results from Multiple Clinical Studies at American Society of Clinical Oncology Annual Conference
SUZHOU, China, and ROCKVILLE, Md., May 25, 2023 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that 4 of its abstracts were selected for presenta...
2023-05-26 10:01
3918
Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting
SHANGHAI, May 25, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting,June 2-6, 2023 in Chicago. The data which include updated analyses of Dizal's two leading assets...
2023-05-26 06:00
3075
Daewoong Pharmaceutical Publishes Molecular Mechanism of Bersiporocin as an Antifibrotic in EMBO Molecular Medicine
* Elucidated molecular mechanism behind safety and efficacy of Bersiporocin * Bersiporocin is currently in Phase II clinical trial for Idiopathic Pulmonary Fibrosis SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Daewoong Pharmaceutical (CEOLee Chang-jae and Jeon Sengho) announced on the 25th...
2023-05-26 06:00
3585
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC Receiving Uliledlimab and Toripalimab Combination Therapy at ASCO 2023
- Uliledlimab is a differentiated monoclonal antibody designed to target CD73 and promote stronger activation ofpatients' immune system against cancer cells. - In newly diagnosed patients who were not eligible for or declined chemotherapy treatment, 63% of the patients with CD73High and PD-L1 T...
2023-05-26 05:01
3081
Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting
- New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment SEOUL, South Korea, May 25, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global leader of AI-powered cancer diagnostics and therapeutics soluti...
2023-05-26 05:00
3150
Hepagene Therapeutics to Present at the European Association for the Study of the Liver (EASL) Congress 2023
SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today announced that Hepagene will present two posters highlighting the preclinical and clinical developm...
2023-05-25 22:00
2578
Leading New Zealand cancer research 'super-charged' by data privacy startup
DUNEDIN, New Zealand, May 25, 2023 /PRNewswire/ -- Two top medical research and biotech innovators today announce a partnership that will supercharge cancer research while providing new levels of health data privacy. Amaroq Therapeutics, a world-leading company based in New Zealand focused on de...
2023-05-25 21:00
2677
HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease
* HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative disorders * Phase 1 clinical trial is ex...
2023-05-25 19:00
3424
Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
June 21, 2023, at The Yale Club, New York City The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the patient journey MELBOURNE, Australia and INDIANAPOLIS, May 2...
2023-05-25 19:00
2788
111 to Announce First Quarter 2023 Unaudited Financial Results on June 15, 2023 - Conference Call to Follow
SHANGHAI, May 25, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results ...
2023-05-25 14:05
2772
TYK2/JAK1 Inhibitor AC-201 of Accropeutics Bioscience gained Human Research Ethics Committees (HREC) permission for Phase I
SUZHOU, China, May 24, 2023 /PRNewswire/ -- Accropeutics Bioscience announced that its oral small molecule TYK2/JAK1 inhibitor AC-201 has been approved by the Australian Human Research Ethics Committee (HREC) to launch a clinical phase I trial inAustralia. The trial will be a randomized, double-b...
2023-05-25 09:51
3554
Clarity's theranostic prostate cancer trial advances to cohort 2
Highlights * Cohort 1 of the SECuRE trial has been completed in 6 participants with metastatic castrate-resistant prostate cancer (mCRPC) who received therapy with 67Cu SAR-bisPSMA at the lowest dose level of 4GBq. * No dose limiting toxicities (DLTs) have been reported in cohort 1. * The Sa...
2023-05-24 21:03
3718
BioRay Filed IND Application for BRY812, a Novel Antibody Drug Conjugate Targeting LIV-1
SHANGHAI, May 24, 2023 /PRNewswire/ -- BioRay Pharmaceutical Co., Ltd. (hereinafter referred to as BioRay) announced that the Investigational New Drug (IND) application for the clinical trial of its proprietary BRY812,a novel antibody-drug conjugate (ADC) targeting human LIV-1 for the treatment o...
2023-05-24 16:14
3112
PharmAbcine Receives IND Approval from the Korean MFDS for Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD
DAEJEON, South Korea, May 23, 2023 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company received IND (Investigational New Drug) approval from the Korean MFDS (Mi...
2023-05-23 20:00
2753
SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum
* Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event. SEONGNAM, Sout...
2023-05-23 20:00
3150
Minghui Pharmaceutical Inc. Announces First-in-Human Dose of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody in Phase 1a Healthy Volunteer Study
SHANGHAI and HANGZHOU, China and WILMINGTON, Del., May 23, 2023 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a clinical-stage biopharmaceutical company focusing on oncology and autoimmune diseases, today announced that the phase1a trial of MHB018A has commenced with the dosing of its first subje...
2023-05-23 19:00
5696
Introducing Ceretone's Core One: The Revolutionary OTC Hearing Aid Launching on Indiegogo in May
ONTARIO, Calif., May 23, 2023 /PRNewswire/ -- Ceretone, the audiology technology innovator, is excited to announce that its latest product, the Core One, will be launched on Indiegogo onMay 30, 2023. The Core One is set to be the smallest over-the-counter (OTC) hearing aid on the market, providin...
2023-05-23 18:01
3055
Week's Top Stories
Most Reposted
HLB's Flagship CIO Fund Launched with Strategic Alliance with Lombard Odier
[Picked up by 281 media titles]
2026-09-28 23:04
Responsible Fintech Institute Appoints Four Executive Fellows and Elevates Distinguished Professor Patrick H. M. Loh to Co-Founder
[Picked up by 279 media titles]
2026-09-29 09:00
Allianz Partners unveils next-generation travel insurance platform to help partners navigate changing landscape
[Picked up by 269 media titles]
2026-09-28 07:30
Zenika CTO Adrien Nortain Moves Base to Singapore to Strengthen Technical Leadership in Asia
[Picked up by 267 media titles]
2026-10-01 10:00
ViewSonic Launches VG1457 Dual-Screen Portable Monitor for Productivity Anywhere
[Picked up by 267 media titles]
2026-09-30 10:50
Most Read
MixVio AI Launches Unified Creative Workspace Across 26 AI Generation Routes
2026-10-02 00:30
22803
Toshiba Information Equipment (Philippines) Celebrates 30th Anniversary and First Shipment from Expanded Nearline HDD Production Line
2026-10-02 21:14
8628
